Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
546 Leser
Artikel bewerten:
(2)

Waters Corporation: Waters Launches New Walk-up Solutions that Further Simplify the Analysis of Biologic Drug Product and Cell Culture Media

News Summary:

  • Updated Waters OneLab software creates new, easy-to-use walk-up solutions integrating Waters BioAccord LC-MS system and Andrew+ robot with upstream bioreactors to automate routine product quality and cell culture media analyses.
  • New pre-developed LC-MS analytical workflows make it even easier for bioprocess engineers with limited LC-MS experience to accelerate upstream process development by up to six weeks.i
  • Automates sample prep and analysis from any bioreactor; available software bridge for Sartorius Ambr® Multi-Parallel Bioreactors provides ease-of-use and seamless data transfer.

MILFORD, Mass., Sept. 12, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announced new bioprocess walk-up solutions designed to further simplify biologic sample prep and analysis. By eliminating the need to send bioreactor samples to a central laboratory for analysis, the new solutions make it even easier to accelerate upstream bioprocess development by up to six weeks over traditional methods.i Enabled by updates to Waters OneLab laboratory automation software and new pre-developed analytical workflows, the combination allows bioprocess engineers to capture high-quality bioprocess and drug product data with just a few clicks.

Waters Corporation

Waters combines its BioAccord liquid chromatography-mass spectrometry (LC-MS) system and the Waters Andrew+ robot connected via new protocols in OneLab software to create fully integrated and easy-to-use bioprocess walk-up solutions. It is designed to enable less experienced LC-MS users to acquire critical quality attribute (CQA) data for analysis of drug product and cell culture media. Capturing data directly at the bioproduction laboratory can help bioprocess engineers improve process understanding, leading to more robust manufacturing processes and accelerated development timelines.

"Waters has made it easier for bioprocess engineers to access rich analytical and CQA data straight from the bioreactor," said Jon Pratt, Senior Vice President, Waters Division. "The integrated combination of software, automation, and pre-developed LC-MS analytical workflows eliminates manual steps previously required for sample preparation, injection, data acquisition, and data transfer. The impact is to reduce human errors and enable process improvements that can ultimately translate to lower downstream costs for manufacturing and drug product prices for patients."

Updated OneLab software is at the heart of the Waters bioprocess walk-up solutions. It incorporates new pre-developed analytical workflows that further simplify the user experience for routine product and process quality measurements of at-line samples from any bioreactor system.

For users of Sartorius Ambr® Multi-Parallel Bioreactors, Waters also provides a software interface to the BioAccord LC-MS system for seamless data transfer. The software interface supports both the Sartorius Ambr® 15 and Ambr® 250 High Throughput Bioreactor Systems.

Waters bioprocess walk-up solutions are now available worldwide through Waters.

Additional Resources

  • Watch our bioprocess walk-up solutions video and visit the solution webpage
  • Read the App Note: "Simplifying Bioreactor In-process Monitoring with Waters Bioprocess Walk-up Solutions"
  • Visit www.waters.com/bioprocessing to learn more about Waters' upstream and downstream bioprocessing solutions
  • Follow and connect with Waters via LinkedIn, Twitter, and Facebook

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With approximately 8,000 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, OneLab, BioAccord, and Andrew+ are trademarks of Waters Corporation. Ambr is a registered trademark of Sartorius.

Contact:

Kevin Kempskie
Senior PR Director, Corporate Communications
Waters Corporation
+1.508.482.2814
pr@waters.com

i Bioprocess engineers typically wait 2-6 weeks for the return of LC-MS sample results from central or outsourced analytical labs according to customers surveyed by Waters; see further detail in Evolving Analytics in the Upstream Lab by Using the Power of LC-MS, a Waters/Sartorius webinar, Nov. 30, 2021

Logo - https://mma.prnewswire.com/media/2071755/Waters_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/waters-launches-new-walk-up-solutions-that-further-simplify-the-analysis-of-biologic-drug-product-and-cell-culture-media-301923855.html

© 2023 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.